11 (31%) were black, and one (3%) was Asian/Pacific Islander (two patients self-identified as white and Hispanic and one as Hispanic only). All but one patient resided in an urban area; one child and none of 29 adults for whom information was available reported international travel. Four patients were part of a recognized shigellosis outbreak (5) . The median duration of illness was 11 days (n = 17). Of patients for whom information was available, 46% (12 of 26) had bloody diarrhea, 50% (16 of 32) had fever, and 45% (19 of 42) were hospitalized. Eighty-one percent (13 of 16) of men for whom information was available were human immunodeficiency virus (HIV)-positive, and 79% (11 of 14) identified as gay, bisexual, or other men who have sex with men (collectively referred to as MSM). Four men reported recent high-risk sexual practices, including anonymous sexual contact (n = 1), sexual contact without a barrier (n = 2 anal-genital; n = 1 oral-anal), and many sexual partners (n = 1); five had a history of syphilis.
All isolates harbored mphA or ermB macrolide resistance genes that are commonly plasmid-encoded. Fifty-three percent (29 of 55) were resistant to five or more classes of antibiotics, and 4% (2 of 55) were resistant to ciprofloxacin. NARMS data indicated that isolates were not susceptible to the drug used for treatment in seven of 19 patients, including three treated with azithromycin.
DSA-Shigella infections are occurring in the United States. Although some of the infections occurred among children, who are often treated with azithromycin for shigellosis, these data suggest that MSM, especially HIV-infected MSM, are currently at greater risk for infection with DSA-Shigella. Shigellosis is more common and can be more severe among HIV-infected persons with CD4 cell counts <200/mm 3 (7) . Clinical failure of azithromycin was recently reported in a Dutch HIV-infected patient with shigellosis (6). Clinicians should be aware that MSM and HIV-positive persons with shigellosis might be infected with Shigella strains with reduced susceptibility to azithromycin. Clinicians should culture stool specimens of MSM and HIV-infected men experiencing diarrhea and determine antimicrobial susceptibility of Shigella to antibiotics other than azithromycin to help guide treatment, if needed. Meticulous handwashing and reducing fecal-oral exposures during sexual contact can reduce risk for infection (7) .
The number of cases presented in this report is likely a substantial underestimate because NARMS routinely tests only 5% of Shigella isolates submitted to public health laboratories, and targeted testing using PFGE might miss cases because Shigella is highly mutable and plasmid-encoded macrolide * Additional information available at http://www.cdc.gov/nczved/divisions/ dfbmd/diseases/shigellosis.
resistance genes are mobile. Additionally, because NARMS began routinely measuring susceptibility to azithromycin in 2011, and recent isolates were more likely to be available for retrospective analysis, these data provide no information about trends. To better track illnesses and guide patient management, clinical laboratory guidelines for azithromycin susceptibility testing among Enterobacteriaceae are urgently needed.
